Last update Oct. 5, 2023
Very High Risk
Ergot alkaloid with dopaminergic effect used as a peripheral vasodilator in cerebral vascular insufficiency, mental deterioration and vertiginous syndrome. Oral, intramuscular or intravenous administration.
At the date of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in clinically significant quantities.
As a dopaminergic agonist, it inhibits prolactin and suppresses lactation. (Aloysio 1988)
It is a non-essential medication, of low therapeutic level (SEFAP 2012, INSALUD 2001), with frequent and important side effects; perfectly dispensable.
We do not have alternatives for Dihydroergocristine Mesilate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM